vs
Side-by-side financial comparison of CLARIVATE PLC (CLVT) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $585.5M, roughly 1.2× CLARIVATE PLC). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -6.9%, a 25.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -1.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $78.9M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -5.1%).
Clarivate Plc is a British-American publicly traded analytics company that operates a collection of subscription-based services, in the areas of bibliometrics and scientometrics; business and market intelligence, and competitive profiling for pharmacy and biotech, patents, and regulatory compliance; trademark protection, and domain and brand protection. Clarivate calculates the impact factor of scientific journals, using data from its Web of Science product family, that also includes services...
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
CLVT vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $585.5M | $708.5M |
| Net Profit | $-40.2M | $135.1M |
| Gross Margin | 67.2% | — |
| Operating Margin | 5.2% | 21.6% |
| Net Margin | -6.9% | 19.1% |
| Revenue YoY | -1.4% | 32.0% |
| Net Profit YoY | 61.3% | 15.5% |
| EPS (diluted) | $-0.06 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $708.5M | ||
| Q3 25 | $623.1M | $659.9M | ||
| Q2 25 | $621.4M | $603.3M | ||
| Q1 25 | $593.7M | $558.6M | ||
| Q4 24 | $663.0M | $536.6M | ||
| Q3 24 | $622.2M | $533.3M | ||
| Q2 24 | $650.3M | $528.1M |
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $135.1M | ||
| Q3 25 | $-28.3M | $111.1M | ||
| Q2 25 | $-72.0M | $90.3M | ||
| Q1 25 | $-103.9M | $114.6M | ||
| Q4 24 | $-191.8M | $117.0M | ||
| Q3 24 | $-65.6M | $96.4M | ||
| Q2 24 | $-304.3M | $88.4M |
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 21.6% | ||
| Q3 25 | 7.1% | 21.5% | ||
| Q2 25 | 1.1% | 20.9% | ||
| Q1 25 | -3.5% | 20.3% | ||
| Q4 24 | -9.4% | 23.4% | ||
| Q3 24 | 3.5% | 21.1% | ||
| Q2 24 | -36.9% | 19.9% |
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 19.1% | ||
| Q3 25 | -4.5% | 16.8% | ||
| Q2 25 | -11.6% | 15.0% | ||
| Q1 25 | -17.5% | 20.5% | ||
| Q4 24 | -28.9% | 21.8% | ||
| Q3 24 | -10.5% | 18.1% | ||
| Q2 24 | -46.8% | 16.7% |
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $4.65 | ||
| Q3 25 | $-0.04 | $3.86 | ||
| Q2 25 | $-0.11 | $3.10 | ||
| Q1 25 | $-0.15 | $3.67 | ||
| Q4 24 | $-0.27 | $3.67 | ||
| Q3 24 | $-0.09 | $3.01 | ||
| Q2 24 | $-0.46 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | $4.3B | — |
| Stockholders' EquityBook value | $4.8B | $459.1M |
| Total Assets | $10.9B | $2.0B |
| Debt / EquityLower = less leverage | 0.89× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $497.0M | ||
| Q3 25 | $318.7M | $285.4M | ||
| Q2 25 | $362.6M | $46.3M | ||
| Q1 25 | $354.0M | $441.4M | ||
| Q4 24 | $295.2M | $669.4M | ||
| Q3 24 | $388.5M | $656.9M | ||
| Q2 24 | $376.4M | $510.9M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — |
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $459.1M | ||
| Q3 25 | $4.9B | $293.6M | ||
| Q2 25 | $5.0B | $172.4M | ||
| Q1 25 | $5.0B | $593.6M | ||
| Q4 24 | $5.1B | $825.5M | ||
| Q3 24 | $5.5B | $881.4M | ||
| Q2 24 | $5.6B | $763.6M |
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $2.0B | ||
| Q3 25 | $11.2B | $1.8B | ||
| Q2 25 | $11.4B | $1.6B | ||
| Q1 25 | $11.5B | $1.9B | ||
| Q4 24 | $11.5B | $2.1B | ||
| Q3 24 | $12.0B | $2.1B | ||
| Q2 24 | $12.1B | $1.9B |
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $134.7M | $192.7M |
| Free Cash FlowOCF − Capex | $78.9M | $188.1M |
| FCF MarginFCF / Revenue | 13.5% | 26.6% |
| Capex IntensityCapex / Revenue | 9.5% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $333.9M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $192.7M | ||
| Q3 25 | $181.1M | $246.2M | ||
| Q2 25 | $116.3M | $148.5M | ||
| Q1 25 | $171.2M | $125.8M | ||
| Q4 24 | $141.3M | $190.7M | ||
| Q3 24 | $202.9M | $149.1M | ||
| Q2 24 | $126.2M | $116.4M |
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $188.1M | ||
| Q3 25 | $115.5M | $235.5M | ||
| Q2 25 | $50.3M | $142.4M | ||
| Q1 25 | $110.3M | $115.8M | ||
| Q4 24 | $59.1M | $183.0M | ||
| Q3 24 | $126.3M | $138.5M | ||
| Q2 24 | $60.3M | $103.5M |
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | 26.6% | ||
| Q3 25 | 18.5% | 35.7% | ||
| Q2 25 | 8.1% | 23.6% | ||
| Q1 25 | 18.6% | 20.7% | ||
| Q4 24 | 8.9% | 34.1% | ||
| Q3 24 | 20.3% | 26.0% | ||
| Q2 24 | 9.3% | 19.6% |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 0.6% | ||
| Q3 25 | 10.5% | 1.6% | ||
| Q2 25 | 10.6% | 1.0% | ||
| Q1 25 | 10.3% | 1.8% | ||
| Q4 24 | 12.4% | 1.4% | ||
| Q3 24 | 12.3% | 2.0% | ||
| Q2 24 | 10.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
